< Terug naar vorige pagina
Onderzoeker
Ignace Vergote
- Disciplines:Gynaecologie en verloskunde, Verpleegkunde, Endocrinologie en metabole ziekten
Affiliaties
- Gynaecologische Oncologie (Afdeling)
Lid
Vanaf1 jan 2012 → Heden
Projecten
11 - 12 of 12
- De continue zoektocht voor de verbetering van de postoperatieve outcomeVanaf1 jun 2013 → 17 jan 2018Financiering: Eigen Middelen zoals patrimonium, inschrijvingsgelden, giften, ....
- OCTIPS.Vanaf1 jan 2012 → 31 dec 2015Financiering: Gezondheid
Publicaties
1 - 10 van 765
- Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.(2024)
Auteurs: Ignace Vergote
Pagina's: 186 - 193 - Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer.(2024)
Auteurs: Toon Van Gorp, Ignace Vergote
Pagina's: 277 - 284 - ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.(2024)
Auteurs: Frédéric Amant, Ignace Vergote
Pagina's: 248 - 266 - Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study(2023)
Auteurs: Ignace Vergote, Els Van Nieuwenhuysen
Pagina's: 5536 - + - GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles(2023)
Auteurs: Ignace Vergote
- Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer(2023)
Auteurs: Toon Van Gorp, Ignace Vergote
Pagina's: 5400 - + - Selinexor in patients with advanced and recurrent endometrial cancer(2023)
Auteurs: Ignace Vergote
- Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ ENGOT-ov38): a phase IIIb trial(2023)
Auteurs: Ignace Vergote
Pagina's: 1152 - 1164 - Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial(2023)
Auteurs: Ignace Vergote
Pagina's: 3556 - 3563 - Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994(2023)
Auteurs: Ignace Vergote
Pagina's: 5035 - +
Patenten
1 - 1 van 1
- Methods for diagnosing ovarian cancer (Inventor)